Illumina, Inc. (NASDAQ:ILMN) Shares Sold by iA Global Asset Management Inc.

iA Global Asset Management Inc. reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 39,022 shares of the life sciences company's stock after selling 5,644 shares during the period. iA Global Asset Management Inc.'s holdings in Illumina were worth $5,089,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Kovitz Investment Group Partners LLC acquired a new stake in shares of Illumina in the 3rd quarter worth $414,000. Wellington Management Group LLP lifted its stake in shares of Illumina by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 30,946 shares of the life sciences company's stock worth $4,036,000 after acquiring an additional 755 shares during the period. Worldquant Millennium Advisors LLC lifted its stake in shares of Illumina by 31.0% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 315,221 shares of the life sciences company's stock worth $41,108,000 after acquiring an additional 74,627 shares during the period. Wahed Invest LLC lifted its stake in shares of Illumina by 13.2% in the 3rd quarter. Wahed Invest LLC now owns 3,867 shares of the life sciences company's stock worth $504,000 after acquiring an additional 451 shares during the period. Finally, Soros Fund Management LLC acquired a new stake in shares of Illumina in the 3rd quarter worth $22,822,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Leerink Partners raised their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Royal Bank of Canada raised their price objective on shares of Illumina from $252.00 to $254.00 and gave the company an "outperform" rating in a research note on Tuesday, November 5th. Citigroup raised their price objective on shares of Illumina from $155.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Hsbc Global Res upgraded shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. Finally, Daiwa America upgraded shares of Illumina to a "strong-buy" rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $164.00.

Illumina Trading Up 0.8 %

Shares of NASDAQ ILMN traded up $1.18 during midday trading on Friday, reaching $141.09. 1,106,683 shares of the stock were exchanged, compared to its average volume of 2,073,166. The company has a market capitalization of $22.38 billion, a P/E ratio of -14.17 and a beta of 1.11. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a 50 day moving average price of $143.12 and a 200-day moving average price of $127.16.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the previous year, the firm earned $0.33 earnings per share. Illumina's revenue was down 3.5% compared to the same quarter last year. Equities research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.